

25 May 2012 EMA/284201/2012

## Agenda – fifth Stakeholders forum on the implementation of the new Pharmacovigilance legislation

25 May 2012, 9.00-17.00pm, room 3A

## Co-chairs: June Raine (morning) / Peter Arlett (afternoon)

Time	Agenda item	Speakers	
08:00 - 09:00	Registration and reimbursement arrangements		
09:00 - 09:15	Welcome and introduction	<b>Noel Wathion</b> <i>European Medicines Agency</i>	
09:15 - 10:00	Update on implementation: July 2012		
	Pharmacovigilance: where we have come from	June Raine Pharmacovigilance Working Party	
	Planning and processes	Peter Arlett	
		European Medicines Agency	
10:00 - 10.30	Update on European Commission's	Florian Schmidt	
	implementing regulation	European Commission	
10:30 - 10:45	Coffee break		
10:45 - 11:30	Session on Good Vigilance Practice		
	Key themes from the consultation and next steps	Priya Bahri European Medicines Agency	
11:30 - 12:30	Session on identification and traceability of biological products		
	Introductory remarks and international	Sabine Brosch	
	initiatives	European Medicines Agency	
	Challenges and perspectives from a Regulatory	Sabine Straus	
	viewpoint	Medicines Evaluation Board,	
		Netherlands	



	Views from the European Generic medicines Association	<b>Suzette Kox</b> <i>European Generic medicines Association</i>	
	Views from the European Federation of Pharmaceutical Industries and Associations/European Biopharmaceutical Enterprises	Peter De Veene  European Federation of  Pharmaceutical Industries and  Associations/European  Biopharmaceutical Enterprises	
12:30 - 13:30	Lunch break		
13:30 - 14:15	Feedback on questions received  Questions and Answers – focus on transitional arrangements	Christelle Bouygues European Medicines Agency	
14:15 - 15:30	General update session		
	Risk Management Plans summaries	Juan Garcia European Medicines Agency	
	Pharmacovigilance and Risk Assessment Committee	Sheila Kennedy European Medicines Agency	
15:30 - 15:45	Coffee break		
15:45 - 16:45	General update session		
	`Article 57' implementation	Ilaria Del Seppia European Medicines Agency	
	Additional monitoring and black symbol	<b>Mick Foy</b> <i>Medicines and Healthcare products Regulatory Agency, UK</i>	
16:45 - 17:00	Conclusions	Co-chairs	
17:00	Close of meeting		

EMA/284201/2012 Page 2/2